The estimated Net Worth of Jack Higgins is at least $282 Tausend dollars as of 15 August 2024. Jack Higgins owns over 19,524 units of Immunome stock worth over $282,317 and over the last few years Jack sold IMNM stock worth over $0.
Sign up
Jack Higgins IMNM stock SEC Form 4 insiders trading
Jack has made over 1 trades of the Immunome stock since 2024, according to the Form 4 filled with the SEC. Most recently Jack exercised 19,524 units of IMNM stock worth $26,357 on 15 August 2024.
The largest trade Jack's ever made was exercising 19,524 units of Immunome stock on 15 August 2024 worth over $26,357. On average, Jack trades about 6,508 units every 0 days since 2023. As of 15 August 2024 Jack still owns at least 19,524 units of Immunome stock.
You can see the complete history of Jack Higgins stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
What's Jack Higgins's mailing address?
Jack's mailing address filed with the SEC is C/O IMMUNOME, INC., 18702 N. CREEK PARKWAY, SUITE 100, BOTHELL, WA, 98011.
Insiders trading at Immunome
Over the last 4 years, insiders at Immunome have traded over $0 worth of Immunome stock and bought 480,004 units worth $5,722,735 . The most active insiders traders include Clay B Siegall, Jean Jacques Bienaime und Michael Rapp. On average, Immunome executives and independent directors trade stock every 84 days with the average trade being worth of $518,362. The most recent stock trade was executed by Jean Jacques Bienaime on 15 August 2024, trading 7,000 units of IMNM stock currently worth $97,580.
What does Immunome do?
Immunome, Inc., a biopharmaceutical company, discovers and develops antibody therapeutics for oncology and infectious disease. The company's lead oncology program includes IMM-ONC-01, which targets IL-38 tumor-derived immune checkpoint capable of promoting evasion of the immune system. It also develops IMM-BCP-01, an antibody cocktail product candidate for the treatment of SARS-CoV-2 infections and COVID-19. The company was incorporated in 2006 and is headquartered in Exton, Pennsylvania.
What does Immunome's logo look like?
Complete history of Jack Higgins stock trades at Immunome
Immunome executives and stock owners
Immunome executives and other stock owners filed with the SEC include:
-
Dr. Purnanand Duddu Sarma,
Pres, CEO & Director -
Sandra G. Stoneman Esq.,
Chief Legal Officer, Gen. Counsel & Corp. Sec. -
Dr. Michael J. Morin Ph.D.,
Chief Scientist -
Dr. Scott K. Dessain M.D., Ph.D.,
Co-founder & Chairman of the Scientific Advisory Board -
Dr. Dennis H. Giesing,
Chief Devel. Officer -
Matthew K. Robinson Ph.D.,
Sr. VP of R&D -
Corleen M. Roche,
Chief Financial Officer -
Michael Widlitz,
Director -
Michael Lefenfeld,
Director -
Dennis H Giesing,
Chief Development Officer -
Jean Jacques Bienaime,
-
Max Rosett,
EVP, Operations & CFO -
James P Boylan,
-
Philip Tsai,
Chief Technology Officer -
Franklyn G Prendergast,
Director -
Sandra M Swain,
-
I Wistar Iii Morris,
10% owner -
Richard F Fitzgerald,
Chief Financial Officer -
John L Lamattina,
Director -
Michael Rapp,
Director -
Corleen M. Roche,
Chief Financial Officer -
Philip Wagenheim,
-
Richard A Baron,
Director -
Matthew K Robinson,
Chief Technology Officer -
Purnanand D Sarma,
President and CEO -
Clay B Siegall,
President and CEO -
Isaac Barchas,
-
Phil Noland Roberts,
Chief Technology Officer -
Carol Schafer,
-
Kinney Horn,
CHIEF BUSINESS OFFICER -
Jack Higgins,
Chief Scientific Officer -
Robert Lechleider,
Chief Medical Officer -
Bruce Turner,
Chief Strategy Officer